Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Despite Headwinds US IPOs Show Few Signs Of Slowing In Q3

This article was originally published in Scrip

Executive Summary

Fifteen drug development firms raised $1.4bn via initial public offerings in the US during the third quarter, which is equal to the quarterly average during the first half of the year and shows that despite recent biotechnology stock headwinds IPOs have not slowed – at least, not yet.

Advertisement

Related Content

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel